Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06974110 · ClinicalTrials.gov registry record · Phase 1
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
A Phase 1 study of Colorectal Cancer and Advanced Solid Tumor, sponsored by MOMA Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 132
- Enrollment target
- 13
- Study locations
NCT06974110: Recruiting Phase 1 study of Colorectal Cancer and Advanced Solid Tumor, sponsored by MOMA Therapeutics.
NCT06974110 is a Phase 1 study of Colorectal Cancer and Advanced Solid Tumor that is actively recruiting participants, run by MOMA Therapeutics. The registered enrollment target is 132 participants, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (91% lower). The trial reports 13 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06974110, a Phase 1 study of Colorectal Cancer and Advanced Solid Tumor, is actively recruiting participants, sponsored by MOMA Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 132 participants
- Enrollment target
- 13
- Study locations
Study Summary
This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-341 administered orally as a single agent or combination therapy in patients with microsatellite instability high (MSI-H) or DNA mismatch repair deficiency (dMMR) solid tumors.
Primary Outcome
To assess the safety and tolerability of MOMA-341 given as a single-agent, and in combination with irinotecan, and in combination with immunotherapy
Conditions Studied
Interventions
- DRUG Irinotecan
- DRUG Immunotherapy
- DRUG MOMA-341
Study Locations (13)
Texas
- Investigative Site #127 - Dallas
- Investigative Site #129 - Houston
New South Wales
- Investigative Site #122 - Sydney
- Investigative Site #123 - Westmead
Florida
- Investigative Site #128 - Tampa
Michigan
- Investigative Site #120 - Detroit
Missouri
- Investigative Site #110 - St Louis
North Carolina
- Investigative Site #131 - Raleigh
Oregon
- Investigative Site #121 - Portland
Queensland
- Investigative Site #124 - Woolloongabba
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2025-07-16 |
| Est. Completion | 2028-05 |
| Phase | Phase 1 |
What NCT06974110 shows while recruiting
NCT06974110 is an interventional study that assigns participants to a tested intervention. The registered 132 participants enrollment target is mid-sized for trials with a published cap, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (91% lower).
The record links to 7 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 3 interventions - of which Irinotecan is the first listed.
NCT06974110 lists 13 locations in 11 states (Texas, New South Wales, Florida).
Frequently Asked Questions
What is clinical trial NCT06974110 about?
NCT06974110 is a clinical study titled "Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors". This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-341 administered orally as a single agent or combination therapy in patients wi...
What is the current status of trial NCT06974110?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 132 participants. The study started on 2025-07-16. Estimated completion is 2028-05.
What conditions does trial NCT06974110 study?
This clinical trial studies the following conditions: Colorectal Cancer, Advanced Solid Tumor, Endometrial Cancer, Gastric Cancer, Metastatic Solid Tumor.
What interventions are being tested in trial NCT06974110?
The interventions under investigation include: Irinotecan (DRUG), Immunotherapy (DRUG), MOMA-341 (DRUG).
Who is sponsoring clinical trial NCT06974110?
This trial is sponsored by MOMA Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06974110 being conducted?
This trial has 13 study locations across Florida, Michigan, Missouri, North Carolina, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06974110's enrollment target sits among peer trials
132 191st of 381 higher than 190 of 381 other Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01766297 · 132 participants · Phase 2
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
- NCT04002947 · 132 participants · Phase 2
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
- NCT04128189 · 132 participants · Phase 3
Shingrix in Renal Transplant Recipients
- NCT04199780 · 132 participants · NA
Effects of tDCS Combined With CBI on Postsurgical Pain
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI